MARKET

DRMA

DRMA

Dermata Therapeutics Inc
NASDAQ
1.380
+0.300
+27.78%
After Hours: 1.290 -0.09 -6.52% 19:59 08/12 EDT
OPEN
1.260
PREV CLOSE
1.080
HIGH
1.460
LOW
1.190
VOLUME
16.78M
TURNOVER
--
52 WEEK HIGH
6.58
52 WEEK LOW
0.9509
MARKET CAP
5.55M
P/E (TTM)
-0.2541
1D
5D
1M
3M
1Y
5Y
1D
Dermata Therapeutics Stock Surges 27% Pre-Market: Why is it Moving?
Benzinga · 16h ago
Why CoreWeave Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
Benzinga · 16h ago
Dermata Therapeutics Reports Q2 2026 Results Ahead Of First Product Launch; Stock Up
NASDAQ · 20h ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 1d ago
Weekly Report: what happened at DRMA last week (0803-0807)?
Weekly Report · 2d ago
Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment
Barchart · 08/05 07:30
Weekly Report: what happened at DRMA last week (0727-0731)?
Weekly Report · 08/03 10:11
Weekly Report: what happened at DRMA last week (0720-0724)?
Weekly Report · 07/27 10:15
More
About DRMA
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.

Webull offers Dermata Therapeutics Inc stock information, including NASDAQ: DRMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DRMA stock methods without spending real money on the virtual paper trading platform.